Having Internalized Material Patents (Class 977/798)
  • Patent number: 8790691
    Abstract: Drag derivatives are provided herein which are suitable for loading into liposomal nanoparticle carriers. In some preferred aspects, the derivatives comprise a poorly water-soluble drag derivatized with a weak-base moiety that facilitates active loading of the drag through a LN transmembrane pH or ion gradient into the aqueous interior of the LN. The weak-base moiety can optionally comprise a lipophilic domain that facilitates active loading of the drag to the inner monolayer of the liposomal membrane. Advantageously, LN formulations of the drag derivatives exhibit improved solubility, reduced toxicity, enhanced efficacy, and/or other benefits relative to the corresponding free drags.
    Type: Grant
    Filed: May 26, 2009
    Date of Patent: July 29, 2014
    Assignee: The University of British Columbia
    Inventors: Pieter Cullis, Marcel Bally, Marco Ciufolini, Norbert Maurer, Igor Jigaltsev
  • Patent number: 8669225
    Abstract: Methods are described for producing non-immunogenic nanoparticles from protein sources by controlling the pH in a nanoprecipitation process. The nanoparticles that are produced by the disclosed methods range in diameter size from about 100 ran to about 400 nm, with a preferred diameter size of from approximately 100 nm to approximately 300 nm, thereby rendering them non-immunogenic. The invention further discloses methods for producing nanoconjugates that are suitable for a variety of therapeutic, diagnostic and other uses.
    Type: Grant
    Filed: May 11, 2009
    Date of Patent: March 11, 2014
    Assignee: South Dakota State University
    Inventors: Omathanu P. Perumal, Satheesh K. Podaralla, Radhey S. Kaushik
  • Publication number: 20130323303
    Abstract: A drug carrier is provided with a structure of a lipid shell enclosing aqueous micelles. The lipid shell includes lipid and emulsifier, in which the emulsifier encloses the lipid. The components of the aqueous micelles are phospholipids and amphiphilic chitosan, and the aqueous micelles enclose an aqueous solution containing a drug. Furthermore, the method of preparing the drug carrier is also provided. Therefore, with the pharmaceutical advantages of lipid-based nanoparticle included low drug leakage and the ability of to overcome the multiple drug resistance, this new formulation were further incorporated with the chitosan and featured with high payload efficiency. The features could enhance intracellular concentration of anti-cancer drug and oral bioavailability.
    Type: Application
    Filed: September 10, 2012
    Publication date: December 5, 2013
    Applicant: NATIONAL CHIAO TUNG UNIVERSITY
    Inventors: San-Yuan CHEN, Chia-Wei SU, Dean-Mo LIU
  • Publication number: 20130101663
    Abstract: This invention describes the use of sTNF-R as a targeting agent attached to liposomes incorporating anti-inflammatory drugs to treat arthritis and other inflammatory diseases. A variety of steroidal and non-steroidal drugs and disease modifying drugs and other anti-inflammatory compounds may be incorporated into the sTNF-R coated liposomes. The sTNF-R coated drug liposomes will accumulate within the inflamed site where the drug is released for maximum therapeutic effect. Other nanosized drug delivery vehicles such as dendrimers, micelles, nanocapsules and nanoparticles may be similarly coated with sTNF-R and used to deliver the drug to the site of inflammation.
    Type: Application
    Filed: August 6, 2012
    Publication date: April 25, 2013
    Inventors: Henry John Smith, James Roger Smith
  • Publication number: 20130089615
    Abstract: The disclosure describes nanocarried and/or microcarried jasmonate compounds and their pharmaceutical compositions, as well as use thereof for treating or preventing angiogenesis-related or NF-?B-related disorders. Also disclosed are methods of making the nanocarried and/or microcarried compounds and their compositions.
    Type: Application
    Filed: September 17, 2012
    Publication date: April 11, 2013
    Applicant: NANOCARE TECHNOLOGIES, INC.
    Inventor: NanoCare Technologies, Inc.
  • Publication number: 20120308663
    Abstract: The present invention relates to nanocapsules, including: a core essentially consisting of a fatty substance, which is liquid or semi-liquid at ambient temperature, and including a hydrophobic active principle and a diethylene glycol ether; an outer lipid shell which is solid at ambient temperature. The lipid nanocapsules of the invention are intended in particular for the manufacture of a drug.
    Type: Application
    Filed: September 24, 2010
    Publication date: December 6, 2012
    Inventors: Emilie Roger, Frederic Lagarce, Jean-Pierre Benoit
  • Publication number: 20120288555
    Abstract: Antiproliferative compositions that include CLEFMA, as well as liposomal compositions containing said antiproliferative compositions, are disclosed. Also disclosed are methods of making and using the antiproliferative compositions and liposomal compositions.
    Type: Application
    Filed: October 24, 2011
    Publication date: November 15, 2012
    Inventors: Vibhudutta Awasthi, Pallavi Lagisetty, Hrushikesh Agashe
  • Publication number: 20120244206
    Abstract: Methods for formulating immediate and sustained release anti-infectives and delivery of such for treatment of respiratory tract infections and other medical conditions, and devices and formulations used in connection with such are described.
    Type: Application
    Filed: October 22, 2007
    Publication date: September 27, 2012
    Inventors: David C. Cipolla, James Blanchard
  • Publication number: 20120201872
    Abstract: Provided herein are methods and compositions for the delivery of bioactive compounds to a cell, tissue, or physiological site. The compositions comprise delivery system complexes comprising liposomes encapsulating a biodegradable ionic precipitate having incorporated therein a bioactive compound and delivery system complexes comprising a biodegradable ionic precipitate ionically bound to a surrounding lipid bilayer, wherein the biodegradable ionic precipitate comprises a bioactive compound. Also provided herein are methods for the treatment of a disease or an unwanted condition in a subject, wherein the methods comprise administering the delivery system complexes comprising bioactive compounds that have therapeutic activity against the disease or unwanted condition to the subject.
    Type: Application
    Filed: August 3, 2010
    Publication date: August 9, 2012
    Applicant: The University of North Carolina at Chapel Hill
    Inventors: Leaf Huang, Jun Li
  • Publication number: 20120128777
    Abstract: The invention is related to compositions which can be used as dermal formulations for supporting the skin to restore normal conditions in case of e.g. irritated skin, or to support medical therapy of skin with atopic dermatitis symptoms, atopic dermatitis, psoriasis or related diseases (e.g. accompanied by distorted barrier function of the skin and microbial load). The compositions of the invention can be used for dermo-cosmetic products but also for pharmaceutical/-medical products, depending on the composition and the additional actives incorporated (cosmetic actives or drugs). The invention is based on the synergistic effect of metallic particles, in particular silver particles (such as microsilver, nanosilver) and lipid particles (lipid nanoparticles or lipid microparticles). As alternatives to silver particles, other metallic particles (e.g. zinc, copper) or nanocrystalline actives can be incorporated (e.g.
    Type: Application
    Filed: October 26, 2009
    Publication date: May 24, 2012
    Applicant: PHARMASOL GMBH
    Inventors: Cornelia Keck, Kay Schwabe, Christian Rimpler
  • Publication number: 20120128589
    Abstract: Described is the use of perfluoro-t-butyl cyclohexane in a contrast agent for molecular imaging, notably F MRI. Particularly, the perfluoro-t-butyl cyclohexane is present in the form of an aqueous emulsion of nanoparticles comprising the perfluoro compound as a core, and an emulsifying agent, such as a phospholipid, as a shell. The shell can be functionalized with other moieties that play a role in imaging, notably ligands for targeted binding and/or contrast agents or labels with a view to other imaging modalities. The latter particularly refers to 1H MRI contrast agents as well as radiolabels for SPECT.
    Type: Application
    Filed: July 21, 2010
    Publication date: May 24, 2012
    Applicant: KONINKLIJKE PHILIPS ELECTRONICS N.V.
    Inventors: Muhammed Yildirim, Holger Gruell, Rudolf Mathias Johannes Nicolaas Lamerichs
  • Publication number: 20120114728
    Abstract: A biodelivery system has been found which increases the efficiency and effectiveness of introducing antimicrobial compounds into complex biofilm matrices through the use of liposome carriers, thereby removing the biofouling in industrial water bearing systems, including piping, heat exchanges, condensers, filtration systems and fluid storage tanks. According to one embodiment of the invention, antimicrobial compound containing liposomes are added to water systems prone to biofouling and biofilm formation. The liposomes, being similar in composition to microbial membranes or cells, are readily incorporated into the existing biofilm. Once the antimicrobial compound containing liposomes become entrained with the biofilm matrix, the decomposition or disintegration of the liposome proceeds. Thereafter the biocidal core is released to react directly with the biofilm encased microorganisms.
    Type: Application
    Filed: February 12, 2010
    Publication date: May 10, 2012
    Inventors: Wilson Kurt Whitekettle, Gloria Jean Tafel, Kimberly Murphy, Qing Zhao
  • Publication number: 20120114719
    Abstract: The present invention provides a topical formulation and method of use where the formulation comprises macqui berry or a macqui berry extract containing anthocyanins having a very high oxygen radical absorbance capacity (ORAC). The formulation provides the macqui berry in a stabilized form which includes a glucuronide or glycuronide, a photostabilizing agent, encapsulation, or light- and/or air-blocking packaging.
    Type: Application
    Filed: September 7, 2011
    Publication date: May 10, 2012
    Applicant: TRACIE MARTYN INTERNATIONAL, LLC
    Inventor: Marius Morariu
  • Publication number: 20120100207
    Abstract: [Problem] To provide a process for producing liposomes, a liposome dispersion or a dry powder of the dispersion by a two-step emulsification method using an additive (dispersing agent) by which a liposome dispersion and a dry powder thereof which can inhibit leakage of an encapsulated drug or the like from liposomes even in the long-term storage and can be stably used over a long period of time are obtained. [Solution to problem] A process for producing liposomes by a two-step emulsification method characterized by using, in the secondary emulsification step, an outer aqueous phase containing a dispersing agent which forms no molecular self-aggregate or a dispersing agent which exclusively forms molecular self-aggregates having a volume mean particle diameter of not more than 10 nm (said dispersing agent being referred to as a “specific dispersing agent” hereinafter), and a process for producing a liposome dispersion or a dry powder thereof utilizing the process for producing liposomes.
    Type: Application
    Filed: June 2, 2010
    Publication date: April 26, 2012
    Applicant: KONICA MINOLTA HOLDINGS, INC.
    Inventors: Yasuyuki Motokui, Takeshi Wada, Takeshi Isoda
  • Publication number: 20120058177
    Abstract: The present invention provides an aqueous tumor-targeting liposome nanoparticle composition comprising an aqueous dispersion of liposome nanoparticles. The nanoparticles preferably encapsulate an anti-cancer chemotherapeutic agent, which can be added to a pre-formed liposome composition or can be incorporated in the liposomes during the formation of the liposomes. The liposome nanoparticles comprise a legumain-targeting lipid admixed with one or more other micelle or vesicle-forming lipid materials in the form of nanoparticulate liposomes dispersed in an aqueous carrier. A preferred tumor-targeting liposome nanoparticle composition comprises (a) a legumain-targeting lipid component, (b) a zwitterionic lipid component; (c) an amino-substituted lipid component; (d) a neutral lipid component; and (e) polyethylene glycol-conjugated lipid component. The legumain-targeting lipid component comprising a hydrophobic lipid portion covalenetly attached to a legumain-binding moiety.
    Type: Application
    Filed: September 2, 2011
    Publication date: March 8, 2012
    Inventors: Ralph A. Reisfeld, Rong Xiang, Yunping Luo, Debbie Liao, Ze Liu, Tingmei Chen, Si Chen, Dan Lu
  • Publication number: 20120052115
    Abstract: Liposomes of a size of less than 200 nanometers target tumors and preferentially deliver imipramine blue to tumors, including brain tumors such as gliomas. The imipramine blue decreases the invasiveness of the tumors, and inhibits tumor metastasis. The liposomes include cholesterol and chemically pure phospholipids that are essentially neutral and contain saturated fatty acids of between 16 and 18 carbon atoms, such as distearoylphosphatidyl choline, and can also include one or more pegylated phospholipids, such as DSPE-PEG.
    Type: Application
    Filed: April 21, 2010
    Publication date: March 1, 2012
    Applicants: Emory University, Georgia Tech Research Corporation
    Inventors: Jennifer M. Munson, Ravi V. Bellamkonda, Jack L. Arbiser
  • Publication number: 20110311442
    Abstract: A lipid vesicle comprising a phospholipid which is a stable vesicle former and at least one unstable vesicle forming member, wherein the unstable vesicle forming member is selected from the group consisting of a polar lipid which is not a stable vesicle former, a PEG, a raft former and a fusion protein is provided. The vesicle can further comprise a biomolecule, such as for example ATP. Methods of using the vesicle for delivery of biomolecules are also provided.
    Type: Application
    Filed: June 17, 2011
    Publication date: December 22, 2011
    Applicant: UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC.
    Inventors: William D. Ehringer, Sufan Chien
  • Patent number: 8067011
    Abstract: The present invention provides a targeted multi-layered drug delivery system for the delivery of cytotoxic agents to B-cells.
    Type: Grant
    Filed: April 9, 2007
    Date of Patent: November 29, 2011
    Assignee: Chimeros, Inc.
    Inventors: Claude Geoffrey Davis, Miguel A. de los Rios, Kenneth J. Oh, Timothy L. Bullock, Patrick T. Johnson, Jacek Ostrowski
  • Publication number: 20110206772
    Abstract: The present invention relates to purification and use of a novel emulsion stabilizing polysaccharide. In particular, a polyelectrolyte exopolysaccharide with high molecular weight comprising a high molecular weight polymer with a tri-saccharide repeating unit is disclosed. In one aspect of the invention, methods are directed to isolating and purifying a high molecular weight exopolysaccharide (EPS) from a cell supernatant. In another aspect, methods are disclosed for isolating a lipopolysaccharide (LPS) and a high molecular weight Acinetobacter polyelectrolyte exopolysaccharide (APE) from Acinetobacter bacteria. Compositions are also directed to lipid nanoparticles comprising a therapeutic agent encapsulated by a high molecular weight polysaccharide and nanoparticles comprising a therapeutic agent bound to a cationic polysaccharide cross-linked with a polyanion.
    Type: Application
    Filed: May 28, 2009
    Publication date: August 25, 2011
    Applicant: TRUSTEES OF TUFTS COLLEGE
    Inventors: David L. Kaplan, Bruce Panilaitis, Michael Mercaldi, Hanna Dams-Kozlowska
  • Publication number: 20110165225
    Abstract: Drag derivatives are provided herein which are suitable for loading into liposomal nanoparticle carriers. In some preferred aspects, the derivatives comprise a poorly water-soluble drag derivatized with a weak-base moiety that facilitates active loading of the drag through a LN transmembrane pH or ion gradient into the aqueous interior of the LN. The weak-base moiety can optionally comprise a lipophilic domain that facilitates active loading of the drag to the inner monolayer of the liposomal membrane. Advantageously, LN formulations of the drag derivatives exhibit improved solubility, reduced toxicity, enhanced efficacy, and/or other benefits relative to the corresponding free drags.
    Type: Application
    Filed: May 26, 2009
    Publication date: July 7, 2011
    Inventors: Peter Cullis, Marcel Bally
  • Publication number: 20110165068
    Abstract: This invention relates to a liposome medicament, and, more particularly, a liposome medicament with targeting function. The liposome medicament includes a medicament that is encapsulated in a liposome, and the medicament contains an effector molecule or an effector molecule that is combined with a first ligand, and a second ligand that is connected onto the surface of the liposome. The first ligand and/or the second ligand can specifically bind to target tissues or target cells to be treated. Preferably, the first ligand and/or the second ligands are antibodies, such as monoclonal antibodies. This invention also relates to a method of preparation of the liposome medicament and use of the medicament for treatment of diseases especially tumors. This invention further relates to a pharmaceutical composition of the liposome medicament and a pharmaceutically acceptable carrier.
    Type: Application
    Filed: December 2, 2010
    Publication date: July 7, 2011
    Inventors: Yanfang Liu, Jia Liu
  • Patent number: 7964196
    Abstract: A self-assembling nanoparticle drug delivery system for the delivery of drugs including peptides, proteins, nucleic acids or synthetic chemical drugs is provided. The self-assembling nanoparticle drug delivery system described herein includes viral capsid proteins, such as Hepatitis B Virus core protein, encapsulating the drug, a lipid bi-layer envelope and targeting or facilitating molecules anchored in the lipid bilayer. A method for construction of the self-assembling nanocparticle drug delivery system is also provided.
    Type: Grant
    Filed: May 25, 2005
    Date of Patent: June 21, 2011
    Assignee: Chimeros, Inc.
    Inventors: Miguel de los Rios, Kenneth J. Oh
  • Publication number: 20110070293
    Abstract: Provided herein are methods for preparing liposomes comprising docetaxel and uses thereof. In certain embodiments, liposomes are prepared without using heat, organic solvents, proteins, and/or inorganic salts in the process. In certain embodiments, the liposomal preparations are used in the treatment of diseases or disorders.
    Type: Application
    Filed: September 23, 2010
    Publication date: March 24, 2011
    Inventors: Indu Javeri, Kaliappanadar Nellaiappan
  • Publication number: 20100266676
    Abstract: The invention relates to nanocapsules with a liquid lipidic core and a solid lipidic shell, the lipidic core being loaded with at least one water-soluble or water-dispersible ingredient, said ingredient being present in the form of a reverse micellar system.
    Type: Application
    Filed: June 11, 2008
    Publication date: October 21, 2010
    Applicant: UNIVERSITE D' ANGERS
    Inventors: Patrick Saulnier, Jean-Pierre Benoit, Nicolas Anton
  • Patent number: 7371738
    Abstract: The present invention relates to the development of a hyaluronic acid and hyaluronic acid hybrid nanoparticle systems for the administration of active molecules, peptides, DNA and/or other hydrophilic or hydrophobic molecules, the composition of hyaluronic acid and hyaluronic acid hybrid nanoparticle systems, and the procedure for their development and use. These nanoparticles are made up of hyaluronic acid in salt form, preferentially the sodium salt of the polymers or hybridized with magnetic Fe particles. The nanoparticles are basically from natural polymers, biocompatibles and biodegradables. The nanoparticles allow the controlled release of the active molecules they transport and their orientation towards the target tissues. The present invention teaches a procedure to elaborate particles of hyaluronic acid with a diameter less than 180 nm., that incorporate an active ingredient, independent of its hydrophilic or hydrophobic nature. Procedures to produce the particles are described.
    Type: Grant
    Filed: April 17, 2006
    Date of Patent: May 13, 2008
    Assignee: University of South Florida
    Inventors: Shyam S. Mohapatra, Bishwabhusan Sahoo, Arun Kumar, Sumita Behera